Bavdegalutamide Explained

Drug Name:	Bavdegalutamide
Cas Number:	2222112-77-6
Pubchem:	134414307
Drugbank:	DB19032
Chemspiderid:	110415899
Unii:	H6NYM0V650
Kegg:	D12316
Chembl:	4862963
Synonyms:	ARV-110
Iupac Name:	N-[4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-[[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl]methyl]piperidin-1-yl]pyridazine-3-carboxamide
C:	41
H:	43
Cl:	1
F:	1
N:	9
O:	6
Smiles:	C1CC(CCC1NC(=O)C2=NN=C(C=C2)N3CCC(CC3)CN4CCN(CC4)C5=C(C=C6C(=C5)C(=O)N(C6=O)C7CCC(=O)NC7=O)F)OC8=CC(=C(C=C8)C#N)Cl
Stdinchi:	InChI=1S/C41H43ClFN9O6/c42-31-19-28(4-1-25(31)22-44)58-27-5-2-26(3-6-27)45-38(54)33-7-9-36(48-47-33)51-13-11-24(12-14-51)23-49-15-17-50(18-16-49)35-21-30-29(20-32(35)43)40(56)52(41(30)57)34-8-10-37(53)46-39(34)55/h1,4,7,9,19-21,24,26-27,34H,2-3,5-6,8,10-18,23H2,(H,45,54)(H,46,53,55)
Stdinchikey:	CLCTZVRHDOAUGJ-UHFFFAOYSA-N

Bavdegalutamide is an experimental proteolysis targeting chimera that functions as a androgen receptor degrader.^[1] It is being developed to treat metastatic castration-resistant prostate cancer.^[2] ^[3] ^[4]

Notes and References

Web site: PubChem . Bavdegalutamide . 2024-10-31 . U.S. National Library of Medicine . en.
Shore ND, Shen J, Devitt ME, Lu H, Alicea J, Parameswaran J, Chirnomas D, Gao X, McKean M . June 2022 . Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer. . Journal of Clinical Oncology . en . 40 . 16_suppl . TPS5106 . 10.1200/JCO.2022.40.16_suppl.TPS5106 . 0732-183X.
Web site: Bavdegalutamide - Arvinas. AdisInsight . Springer Nature Switzerland AG .
Jia X, Han X . Targeting androgen receptor degradation with PROTACs from bench to bedside . Biomedicine & Pharmacotherapy . 158 . 114112 . February 2023 . 36508999 . 10.1016/j.biopha.2022.114112 . free .